Literature DB >> 12971676

Drug susceptibility testing of Mycobacterium tuberculosis to fluoroquinolones: first experience with a quality control panel in the Nordic-Baltic collaboration.

I S Johansen1, A R Larsen, P Sandven, B Petrini, H Soini, K Levina, A Sosnovskaja, G Skenders, S Hoffner.   

Abstract

In the first attempt to establish a quality assurance programme for susceptibility testing of Mycobacterium tuberculosis to fluoroquinolones, 20 strains with different fluoroquinolone susceptibility patterns were distributed by the Supranational Reference Laboratory in Stockholm to the other mycobacterial reference laboratories of the Nordic and Baltic countries. Susceptibility testing to fluoroquinolones was performed according to routine procedures in each laboratory. Results were compared to sequence analysis of the gyrA gene and minimal inhibitory concentration determination. Most laboratories found identical susceptibility patterns. The two resistant strains were correctly identified by all laboratories, but three laboratories each falsely reported one susceptible strain as resistant. These results indicate that the participating laboratories yield reliable results in detection of fluoroquinolone-resistant strains, although the need for a standardised quality assurance programme for drug susceptibility testing for fluoroquinolones is stressed by the strains falsely reported as resistant.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12971676

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  2 in total

1.  External Quality Assessment for Tuberculosis Diagnosis and Drug Resistance in the European Union: A Five Year Multicentre Implementation Study.

Authors:  Vladyslav Nikolayevskyy; Doris Hillemann; Elvira Richter; Nada Ahmed; Marieke J van der Werf; Csaba Kodmon; Francis Drobniewski; Sabine Ruesch-Gerdes
Journal:  PLoS One       Date:  2016-04-07       Impact factor: 3.240

2.  First evaluation after implementation of a quality control system for the second line drug susceptibility testing of Mycobacterium tuberculosis joint efforts in low and high incidence countries.

Authors:  Doris Hillemann; Sven Hoffner; Daniela Cirillo; Francis Drobniewski; Elvira Richter; Sabine Rüsch-Gerdes
Journal:  PLoS One       Date:  2013-10-11       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.